Jyothi Datta is a journalist for businessline, covering a wide range of topics including healthcare, pharmaceuticals, and business. With a focus on providing in-depth analysis and reporting on current issues, Jyothi's articles aim to inform and educate readers on the latest developments in the industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Jyothi Datta's coverage primarily focuses on healthcare and pharmaceuticals, with a strong emphasis on COVID-19, medical research, vaccines, public health, and healthcare. She frequently covers government announcements and press releases in her articles.
Given the nature of Jyothi's coverage, she would likely be interested in pitches that offer expert insights into the latest developments in healthcare policies or breakthroughs in medical research. Furthermore, sources who can provide data-driven analysis related to public health trends or vaccine efficacy may find success when reaching out to Jyothi.
Although no specific geographic focus is indicated for Jyothi's coverage attributes suggests that she takes an international view of healthcare topics. Therefore, experts from around the world could potentially engage effectively with her through relevant and insightful pitches.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Stringent steps needed to keep India label safe from fly-by-night operators
By: Jyothi Datta
India among five countries contributing to over half the global disease burden
Global survey reveals clinicians' attitudes towards AI in healthcare, highlighting concerns over information accuracy and critical thinking skills.
By: Jyothi Datta
Monopoly could hinder Union Health Ministry's efforts “to benefit from domestic production and competitive pricing through pooled procurement strategies”
Trump’s second term unlikely to upset the Indo-US pharma apple-cart, say industry voices
By: Jyothi Datta
GLP-1 products going off patent in some markets includes popular Type-2 diabetes and weight-loss drug Ozempic
By: Jyothi Datta
RFK had trained his guns on US health agencies, including the FDA
Medical device makers call for a regulatory framework on refurbished imports
By: Jyothi Datta
IP experts concerned on impact this could have on other biosimilar contenders
In the last two years, NE-VL agreements have dipped to just two (in the review period), compared to six in Index 2022, says the report brought out by ATMF, a Netherlands-based non-profit organisation
(833) 317-6278 
